Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025

BRISBANE, Calif., July 22, 2025 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, August 5, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the second quarter 2025.

Live audio of the webcast will be accessible on Day One’s Events on the Day One Media & Investors page. An archived version of the webcast will be available for replay on the News & Events section of the Day One Media & Investors page for 30 days following the event.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment, Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer – regardless of age – starting from day one.

Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company’s pipeline includes tovorafenib (OJEMDA™) and DAY301.

Day One is based in Brisbane, California. For more information, please visit www.dayonebio.com or find the Company on LinkedIn or X.

Day One uses its Investor Relations website (ir.dayonebio.com), its X handle (x.com/DayOneBio), and LinkedIn Home Page (linkedin.com/company/dayonebio) as a means of disseminating or providing notification of, among other things, news or announcements regarding its business or financial performance, investor events, press releases, and earnings releases, and as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

DAY ONE MEDIA
Laura Cooper, Head of Communications
media@dayonebio.com

DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com

Staff

Recent Posts

Healthcare Triangle, Inc. Announces 1-for-60 Reverse Stock Split as Part of Nasdaq Compliance Plan

PLEASANTON, Calif., Feb. 6, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"),…

5 hours ago

Rokt Joins American Heart Association’s “Go Red. Shop with Heart” Initiative, Marks Kickoff at NYSE Bell Ringing

NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Rokt, the leading ecommerce technology company using machine learning…

5 hours ago

CIMG Inc. Receives 2025 “High-Quality Listed Company Award” Recognition

HONG KONG, Feb. 6, 2026 /PRNewswire/ -- CIMG Inc. ("CIMG" or the "Company") (Nasdaq: IMG),…

5 hours ago

Airrosti Launches REACH, Bringing a Proven Clinical Breakthrough in Musculoskeletal Care to a National Digital Platform

Validated by Claims Study dated, December,10, 2025, Airrosti providers showed $3.6K+ in savings per member…

5 hours ago

ACG Packaging Materials Joins World Economic Forum’s Global Lighthouse Network as World’s First Pharmaceutical Packaging Company

DAVOS, Switzerland and MUMBAI, India, Feb. 6, 2026 /PRNewswire/ -- ACG Packaging Materials today announced…

5 hours ago

CaseBioscience® Launches CaseCryo® CTG DMSO and CaseStor® HSS at ATW 2026, Advancing Next-Generation Biopreservation for Cell Therapy

Introducing cell therapy–grade cryopreservation and hypothermic storage solutions designed for consistency, quality, and performance across…

5 hours ago